Latest news
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Cancer LetterThe Cancer Letter · Fri, 07 Aug 2026 20:50:43 GMTThird time’s the charm for Replimune as melanoma drug earns FDA greenlight - BioSpaceBioSpace · Thu, 06 Aug 2026 22:18:12 GMTChaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad - BioSpaceBioSpace · Wed, 05 Aug 2026 13:39:37 GMTFDA Action Update, July 2026: Approval, Acceptances, and Advisory Committee Vote - NeurologyLiveNeurologyLive · Mon, 03 Aug 2026 15:05:04 GMTFDA Panel Votes Against Deramiocel for DMD Cardiomyopathy - Endocrinology AdvisorEndocrinology Advisor · Mon, 03 Aug 2026 04:00:00 GMTFDA Advisory Committee Backs RP1 for Advanced Melanoma - Cure TodayCure Today · Sun, 02 Aug 2026 14:37:01 GMTFDA AdComm Votes Against Recommending Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in AD, Salanersen's FDA Breakthrough Designation Meaning - NeurologyLiveNeurologyLive · Sat, 01 Aug 2026 23:14:57 GMTFDA advisory committee backs RP1 efficacy in anti-PD-1–refractory advanced melanoma - AllSciAllSci · Fri, 31 Jul 2026 12:34:55 GMT